

ESDO-FFCD MASTERCLASS II October 5 - 6, 2018 IMMUNOLOGY AND CANCER: FROM BENCH TO BEDSIDE



PALAIS DU PHARO MARSEILLE, FRANCE <http://palaisdupharo.marseille.fr>

International experts will teach on the latest discoveries of Immunotherapy for Digestive Cancers with multidisciplinary views. The 2nd ESDO-FFCD MASTERCLASS is organised during 2 days by the **European Society of Digestive Oncology** and the **Francophone Federation of Digestive Oncology**.

Scientific Committee:

Thomas Aparicio, Laetitia Dahan, Thomas Gruenberger, Côme Lepage, Tamara Matysiak, Pierre Michel, Jean-Marc Phelip, Wolff Schmiegel, Jean-Francois Seitz, Thomas Seufferlein, Julien Taieb, Eric Van Cutsem, Jean-Luc Van Laethem

Faculty :

Jaafar Bennouna, Nantes
Franck Carbonel, Paris
Nathalie Chaput, Paris
Laëtitia Dahan, Marseille
Jean-Jacques Grob, Marseille
Ulrich Güller, St. Gallen
Regis Josien, Nantes
Pierre Laurent-Puig, Paris
Egesta Lopci, Milan

Laura Mezquita, Paris
Dominik Modest, Munich
Simon Pernot, Paris
Jens Ricke, Munich
Sacha Rothschild, Basel
Thomas Seufferlein, Ulm
David Tougeron, Poitiers
Eric Van Cutsem, Leuven
Eric Vivier, Marseille

Organization & Registration:

Liz Tanzer masterclass@esdo.eu
tel. +43 676 707 6079

ESDO c/o VMA, 1090 Vienna, Alser Strasse 4

Onsite Organization & Accreditation:

Aurélie Gaudron aurelie.gaudron@u-bourgogne.fr

FFCD tel. +33 03 80 38 13 14

21079 DIJON Cedex, 7 Boulevard Jeanne d'Arc

MASTERCLASS II PROGRAMME

IMMUNOLOGY AND CANCER: FROM BENCH TO BEDSIDE

FRIDAY 5 October 2018

8:30 Welcome Eric Van Cutsem, Pierre Michel, Côme Lepage

9:00-10:30

★ **Basis**

Chairs: Laëtitia Dahan, Jean-Luc Van Laethem

- Immunology for Dummies: **Regis Josien, Nantes**
General immunology excluding cancer: primary & secondary lymphoid organs, different cellular actors, innate / acquired immunity
- Immunology and tumours: **Nathalie Chaput, Paris**
Immunosurveillance, immunoescape, immunoediting
- Basis of anti-cancer immunotherapy: mechanisms of action: **Eric Vivier, Marseille**
Induction of T-cytotoxicity (vaccines, cytokines, adoptive transfer), triggering of innate immune response, checkpoint inhibitors, etc

10:30-11:00 break

11:00-12:00

★ **Tumor immunology and diagnosis**

Chairs: Jens Ricke, Julien Taieb

- Future approach to cancer classification: **Pierre Laurent-Puig, Paris**
- Immunology-based PET/CT-imaging: **Egesta Lopci, Milano**
where are we now and where are we heading?

12:00-13:00

★ **Major results of immunotherapy in non-digestive cancers: change of paradigm**

Chairs: Jaafar Bennouna, Tamara Matysiak

- The example of melanoma: **Jean-Jacques Grob, Marseille**
- The example of lung cancers: **Jaafar Bennouna, Nantes**

13:00-14:00 lunch

14:00-15:30

★ **Management of Immunotherapy**

Chairs: Jean-Jacques Grob, Côme Lepage

- Practical management of toxicities of immunotherapy in cancer patients: **Ulrich Güller, St. Gallen**
- How to assess the response to immunotherapy? **Jens Ricke, Munich**
CHOI, RECIST, Immune-Related Response Criteria, depth of response, earliness of response
- Immunomodulation using anti-angiogenic agents: **Simon Pernot, Paris**

15:30-16:00 break

MASTERCLASS II PROGRAMME

IMMUNOLOGY AND CANCER: FROM BENCH TO BEDSIDE

16:00-17:00

★ **The results of immunotherapy in digestive cancers: what happened until 2018?**

Chairs: Jean-Marc Phelip, Eric Van Cutsem

- Non colorectal: **David Tougeron, Poitiers**
- Colorectal: **Julien Taieb, Paris**

17:30 **ROUND TABLE DISCUSSION**

SATURDAY 6 October 2018

9:00-10:30

★ **Strategy of treatment with immunotherapy**

Chair: Thomas Seufferlein

- How to sequence immunotherapy, when to discontinue immunotherapy ?
- Predictive markers of efficacy
- Microbiote & immunotherapy

Sacha Rothschild, Basel

Laura Mezquita, Paris

Franck Carbonel, Paris

10:30-11:00 break

11:00-13:00

★ **The future of immunotherapy in digestive oncology**

Chairs: Wolff Schmiegel, David Tougeron

- Combination of drugs acting on the immune system **Dominik Modest, Munich**
(therapeutic combinations immuno-chemotherapy / radiotherapy)
- Which therapeutic trials for the future

Therapeutic combinations, resistance mechanisms, new immunomodulatory targets, cell therapies, novel antibodies, T-cell immune conjugates, biomarkers

- non colorectal: **Eric van Cutsem, Leuven**
- colorectal: **Thomas Seufferlein, Ulm**

13:00 **ROUND TABLE DISCUSSION**

13:30 End of Programme

supporting partners

